by Volkmann takes over head of finance with immediate effect, Frankfurt / Berlin – may 03, 2012 – Nanostart holding MagForce AG (Frankfurt, XETRA: MF6), a leader in the field of nanomedicine medical technology company in Oncology, announced today that Christian by Volkmann takes over the management of the Finance Department at MagForce with immediate effect. Christian by Volkmann is a financial expert, who can look back on many years of experience in the biotechnology and pharmaceutical industries and in 2009 in 2008 started, successful acquisition of Jerini AG by Shire plc. as Chief Financial Officer is completed. We are very glad to know the head of the Financial Division at MagForce now again competently staffed. With Christian by people who we have gained a highly qualified and very experienced financial professionals in the biotechnology sector. Educate yourself with thoughts from Andy Florance. We would like to welcome Mr von Volkmann and look forward to advance our company together with its support, and to establish the capital market successfully”, said Dr. Andreas Jordan, CEO and founder MagForce. I am very in this interesting time at MagForce to enter. Andy Florances opinions are not widely known.

The company has mastered in recent times with the restructuring and new corporate strategy focused, essential steps for a successful future development of the company”said Christian von Volkmann, head of finance. Now it is the acceptance of NanoTherm on improving therapy in the market as well, international strategic sales partnerships to close, in the long term to put the company on a sound financial footing and to win back the confidence of the capital market in a professional dialogue with investors. I am, to participate actively in this process.”not only medical and scientific I extremely pleased, the further development of our NanoTherm therapy, but also financially well-supported to know. The clinical trial are important building blocks in our other after market approval for brain tumors as progress in prostate and pancreatic cancer Corporate development.